2Alberti KG,Zimmet P,Shaw J,et al.The metabolic syndrome-a new worldwide definition.Lancet,2005,366:1059-1062.
3Kahn R,Buse J,Ferrannini E,et al.The metabolic syndrome:time for a critical appraisal:joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care,2005,28:2289-2304.
4Einhorn D,Reaven GM,Cobin RH,et al.American college of endocrinology position statement on the insulin resistance syndrome.Endocr Pract,2003,9:237-252.
5Mechanick JI,Cobin RH,Einhorn D,et al.American college endocrinology/American association of clinical endocrinologists:reaffirmation of the 2003 ACE insulin resistance syndrome (IRS) position statement.Proceeding of 3rd Annual world congress on the insulin resistance syndrome,San Francisco,2005.
6Reaven GM.Role of insulin resistance in human disease.Diabetes,1988,37:1595-1607.
8Hills SA,Balkau B,Coppack SW,et al.The EGIR-RISC STUDY (The European group for the study of insulin resistance:relationship between insulin sensitivity and cardiovascular disease risk):Ⅰ.Methodology and objectives.Diabetologia.2004,47:566-570.
9Bloomgarden ZT.Concepts of insulin resistance.Metabolic Syndrome and Related Disorders,2005,3:284-293.
10Kahn CR.Insulin action,diabetogenes,and the cause of type Ⅱ diabetes.Diabetes,1994,43:1066-1084.
二级参考文献22
1Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med,2003,4(suppl 6):s11-s18.
2Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol,1994,73:460-468.
3Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med,2003,115(suppl 8A):24s-28s.
4Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care,2003,26:1513-1517.
5Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes,2001,109:s548-559.
6Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001,285:1585-1591.
7Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004,27:1182-1186.
8Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003,26:3230-3236.
9Tuomilehto J, Lindstrm J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM, 2001,344:1343-1350.
10Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet,2003,361:2005-2016.
